SGMT Stock Analysis: Sagimet Biosciences Series | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 470m USD | 12M Return: -11.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.17M
Warnings
Tailwinds
Seasonality 2.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sagimet Biosciences Inc. (NASDAQ: SGMT) is a clinical-stage biopharmaceutical company headquartered in San Mateo, California, that develops novel therapeutics called fatty acid synthase (FASN) inhibitors targeting metabolic and fibrotic diseases. Its lead candidate, Denifanstat, is an oral, once-daily selective FASN inhibitor being studied for metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer, with additional programs including TVB-3567 for acne and preclinical oncology candidates for solid tumors and glioblastoma.
The company was incorporated in 2006 as 3-V Biosciences, Inc. and rebranded as Sagimet Biosciences in August 2019 before going public on July 14, 2023, with a small-cap market capitalization of approximately $400 million. It operates within the GICS Biotechnology sub-industry, where clinical-stage biopharmaceutical companies typically fund operations through equity financings and partnerships rather than commercial product revenue, relying on clinical trial outcomes and regulatory milestones to drive long-term value.
- Denifanstat Phase 3 MASH readout remains key clinical catalyst
- Competition intensifies from Madrigals approved Rezdiffra in MASH
- Limited cash runway fuels dilution risk concerns for shareholders
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.37 > 0.02 and ΔFCF/TA -2.14 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.37 > 3% & CFO -39.7m > Net Income -43.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 20.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.6m) vs 12m ago 1.13% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.95 (Total Current Assets 107.7m - Total Current Liabilities 5.30m) / Total Assets 107.8m |
| B: -3.31 (Retained Earnings -357.0m / Total Assets 107.8m) |
| C: -0.38 (EBIT TTM -48.7m / Avg Total Assets 127.0m) |
| D: 19.34 (Book Value of Equity 102.5m / Total Liabilities 5.30m) |
| Altman-Z'' = 13.16 = AAA |
As of July 08, 2026, the stock is trading at USD 7.69 with a total of 1,340,901 shares traded. Over the past week, the price has changed by -1.28%, over one month by +17.76%, over three months by +51.38% and over the past year by -11.41%.
Current recommended Stop Loss: 6.80 (which is 11.6% or 2.1 ATR below the current price).
Sagimet Biosciences Series has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy SGMT.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 26.2 | 240.7% |
P/S = 52.4983
P/B = 4.4992
Revenue TTM = 0.0 USD
EBIT TTM = -48.7m USD
EBITDA TTM = -48.7m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 39.0k USD (from shortTermDebt, last quarter)
Debt = 39.0k USD (from shortLongTermDebtTotal, last quarter) (leases 39.0k already included)
Net Debt = -104.5m USD (calculated: Debt 39.0k - CCE 104.5m)
Enterprise Value = 365.4m USD (469.9m + Debt 39.0k - CCE 104.5m)
Interest Coverage Ratio = unknown (Ebit TTM -48.7m / Interest Expense TTM 0.0)
EV/FCF = -9.20x (Enterprise Value 365.4m / FCF TTM -39.7m)
FCF Yield = -10.87% (FCF TTM -39.7m / Enterprise Value 365.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 3.39 (Enterprise Value 365.4m / Total Assets 107.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 39.0k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -38.5m (EBIT -48.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 20.34 (Total Current Assets 107.7m / Total Current Liabilities 5.30m)
Debt / Equity = 0.00 (Debt 39.0k / totalStockholderEquity, last quarter 102.5m)
Debt / EBITDA = 2.14 (negative EBITDA) (Net Debt -104.5m / EBITDA -48.7m)
Debt / FCF = 2.63 (negative FCF - burning cash) (Net Debt -104.5m / FCF TTM -39.7m)
Total Stockholder Equity = 115.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.27% (Net Income -43.5m / Total Assets 107.8m)
RoE = -37.57% (Net Income TTM -43.5m / Total Stockholder Equity 115.8m)
RoCE = -42.08% (EBIT -48.7m / Capital Employed (Equity 115.8m + L.T.Debt 0.0))
RoIC = -37.56% (negative operating profit) (NOPAT -38.5m / Invested Capital 102.5m)
WACC = 13.36% (E(469.9m)/V(470.0m) * Re(13.36%) + D(39.0k)/V(470.0m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.36% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 94.39 | Cagr: 29.52%
[DCF] Fair Price = unknown (Cash Flow -39.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.08 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.27 | Chg30d=+0.00% | Revisions=+70% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.26 | Chg30d=+0.00% | Revisions=+50% | Analysts=9
EPS current Year (2026-12-31): EPS=-1.22 | Chg30d=+0.00% | Revisions=+50% | GrowthEPS=+22.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.31 | Chg30d=+0.00% | Revisions=+55% | GrowthEPS=-7.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +72% (up=26, down=3)